After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. ... Read more
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced ... Read more
Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to develop a new “off-the-shelf” immunotherapy for ... Read more
The European Commission (EC) has approved Bavencio (avelumab) as a first-line maintenance treatment for adults with advanced urothelial carcinoma, the most common form ... Read more
The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for the treatment of certain non-small cell lung ... Read more
The European Commission has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy as a first-line treatment ... Read more
The U.S. Food and Drug Administration (FDA) has agreed to review applications requesting the approval of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for people ... Read more
A committee of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of people with advanced, inoperable, ... Read more
